In the few studies evaluating the prognostic impact and predictive value of sarcopenia in NSCLC patients harboring EGFR mutations and treated with EGFR-TKIs, as with ICI therapies, the results are inconsistent; however, most studies agree that sarcopenia does not affect PFS and OS (30–32). This evidence concerns the gene EGFR and sarcopenia.